---
schema_version: "secwatch.filing_event.v1"
accession: "0001919246-26-000110"
form_type: "8-K"
ticker: "PTHS"
cik: "0001919246"
company_name: "Pelthos Therapeutics Inc."
filed_at: "2026-08-13T11:00:34+00:00"
generated_at: "2026-08-13T11:05:29.710180+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Pelthos Therapeutics restates Q1 2026 results due to convertible debt valuation error

## Summary
- Non-reliance on Q1 2026 10-Q; restatement due to ASC 820 misapplication for Level 3 convertible debt fair value.
- Restatement increases convertible debt fair value by $15.8M, accumulated deficit by $14.8M, reduces AOCI by $1.0M.
- Non-cash expense up $14.8M; no impact on revenue, operating expenses, or cash position.
- Material weakness in internal controls over Level 3 fair value measurements; remediation planned.

## SEC filing metadata
- accession: 0001919246-26-000110
- form_type: 8-K
- ticker: PTHS
- cik: 0001919246
- company_name: Pelthos Therapeutics Inc.
- filed_at: 2026-08-13T11:00:34+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 4.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1919246/000191924626000110/0001919246-26-000110-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1919246/000191924626000110/pths-20260812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001919246-26-000110
- JSON: https://secwatch.observer/filing/0001919246-26-000110.json
- Plain text: https://secwatch.observer/filing/0001919246-26-000110.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.